Nanjing Leads Biolabs Wins HKEX Approval for H-Share Full Circulation
I'm LongbridgeAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing of 44,391,598 converted H shares under its H Share Full Circulation program. This conversion involves 23 shareholders and aims to enhance liquidity and marketability of the company's equity. The move is expected to broaden the investor base and strengthen its position in the biotech sector. The latest analyst rating for the stock (HK:9887) is a Buy with a price target of HK$100.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments